NVO - NOVO NORDISK A S

QQQ $ 472.49 $ -2.05 (-0.43 %)

DIA $ 416.26 $ -1.07 (-0.26 %)

SPY $ 562.20 $ -1.67 (-0.3 %)

TLT $ 99.62 $ -1.25 (-1.24 %)

GLD $ 235.53 $ -1.83 (-0.77 %)

Previous Close

$ 132.06

Open

$ 132.70

Bid

$ 132.00 x 300

Ask

-- x --

Day's Range

$ 131.32 - $ 133.23

52 Week Range

$ 86.02 - $ 147.60

Volume

2,777,326

Average Volume

Market Cap

595,591

Beta (5Y Monthly)

$ 0.67

PE Ratio (TTM)

$ 0.00

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.01)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

novo-nordisk-inks-600m-genetic-medicines-pact-with-canadian-firm-to-target-cardiometabolic-indications

Novo Nordisk Inks $600M Genetic Medicines ...
09/18/2024 19:30:12

NanoVation Therapeutics partners with Novo Nordisk to develop genetic medicines for cardiometabolic and rare diseases, utilizin...

NanoVation Therapeutics Announces Multi-Ye...
09/18/2024 12:11:31

Benzinga Market Summary: Bitcoin Rises, Oi...
09/17/2024 20:01:40

Novo's Otte Says Company Is Prepared For N...
09/17/2024 17:12:40

- Bloomberg

Cantor Fitzgerald Reiterates Overweight on...
09/16/2024 16:23:19

Cantor Fitzgerald analyst Louise Chen reiterates Novo Nordisk (NYSE:NVO) with a Overweight and maintains $160 price target.

Korro Bio Announces Collaboration With Nov...
09/16/2024 12:12:03

Partnership leverages Korro's proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits into two undisc...

if-you-invested-1000-in-this-stock-10-years-ago-you-would-have-5700-today

If You Invested $1000 In This Stock 10 Yea...
09/11/2024 18:30:58

Roche Says In CT-996 Phase 1 Trial, 4-Week...
09/11/2024 15:49:52

- Reuters

ozempic-maker-novo-nordisk-touts-encouraging-data-from-new-obesity-pill-showing-double-weight-loss-compared-to-wegovy

Ozempic Maker Novo Nordisk Touts Encouragi...
09/11/2024 13:13:52

Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight loss...

novo-nordisk-reports-positive-results-of-weight-loss-drug-liraglutide-for-children-as-young-as-6-eyes-fda-and-ema-approval

Novo Nordisk Reports Positive Results Of W...
09/11/2024 08:19:30

Novo Nordisk has announced that its weight-loss drug liraglutide is safe and effective for children as young as six. The compan...

Evaluating Novo Nordisk: Insights From 8 F...
09/09/2024 17:00:42

Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:50:36

Cantor Fitzgerald analyst Louise Chen reiterates Novo Nordisk (NYSE:NVO) with a Overweight and maintains $160 price target.

what-the-options-market-tells-us-about-novo-nordisk

What the Options Market Tells Us About Nov...
09/06/2024 16:16:15

goldman-sachs-shifts-stance-on-novartis-cites-lack-of-near-term-catalysts

Goldman Sachs Shifts Stance On Novartis, C...
09/05/2024 18:34:15

Goldman Sachs downgrades Novartis to Neutral, citing a lack of immediate innovative catalysts and limited stock growth potential.

fake-ozempic-targets-weight-loss-market-forged-batches-an-international-concern

Fake Ozempic Targets Weight-Loss Market: F...
09/05/2024 17:17:20

Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation...

battle-over-compounded-weight-loss-medications---sustainability-and-regulation

Battle Over Compounded Weight-Loss Medicat...
09/05/2024 16:47:47

Explore how Hims & Hers competes with big pharma amid weight-loss drug shortages, offering cheaper alternatives and facing ...

Novo Nordisk Unusual Options Activity
09/05/2024 15:32:05

ascendis-pharma-faces-challenges-with-skytrofa-and-yorvipath-pricing-analysts-weigh-in

Ascendis Pharma Faces Challenges With Skyt...
09/04/2024 21:02:35

Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included...

bioage-labs-files-for-100m-ipo-becomes-the-new-entrant-in-obesity-drugs-race

BioAge Labs Files For $100M IPO, Becomes T...
09/04/2024 15:13:09

BioAge Labs a biotech company focused on therapies for metabolic diseases, has filed for a $100 million IPO. Founded in 2015, t...

MHRA Finds No Evidence Supporting Link Bet...
09/04/2024 14:52:07

- Reuters